Ginkgo divests biosecurity arm; J&J’s early prostate cancer datanews2026-02-27T15:14:31+00:00February 27th, 2026|Endpoints News|
Padcev-Keytruda combo delivers more positive data in bladder cancernews2026-02-27T15:00:05+00:00February 27th, 2026|Endpoints News|
Novartis closes Avidity deal as rare heart disease spinout launchesnews2026-02-27T14:51:42+00:00February 27th, 2026|Endpoints News|
Investors are pumping money into AI tools for health insurersnews2026-02-27T14:00:27+00:00February 27th, 2026|Endpoints News|
Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the futurenews2026-02-27T12:11:21+00:00February 27th, 2026|Endpoints News|
Doug Ingram’s uneven legacy at Sarepta; Merck splits human health business, brings in Sanofi execnews2026-02-27T12:00:10+00:00February 27th, 2026|Endpoints News|
DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case news2026-02-26T20:42:26+00:00February 26th, 2026|Endpoints News|
Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart news2026-02-26T20:17:18+00:00February 26th, 2026|Endpoints News|
FDA probes internal Prasad complaints with outside helpnews2026-02-26T20:13:02+00:00February 26th, 2026|Endpoints News|
Boehringer wins accelerated approval for first-line use of lung cancer drugnews2026-02-26T20:03:47+00:00February 26th, 2026|Endpoints News|
